Obesity is a chronic disease. Default is long-term continuation. Discontinuation produces regain (STEP-4).
STEP-4 finding
STEP-4 (JAMA 2021) randomized patients completing 20 weeks of semaglutide titration to continue vs placebo. Continuation: additional weight loss to ~17%. Withdrawal: ~7% regain. This is why obesity is framed as chronic disease.
Implications
The question is not 'when do I stop' but 'how do I make this sustainable.' Plan cost, refill logistics, side-effect management, lifestyle support.
If you discontinue
- Regain is default. Some patients maintain with intensive lifestyle change.
- Plan timing.
- Resume earlier if regain occurs and you want to control it.
- Re-titrate if off >few weeks.
When appropriate
- Pregnancy planning (washout required)
- Severe persistent side effects
- Lack of efficacy at adequate dose after adequate trial
- Personal choice after informed counseling
Maintenance dose decisions
Many patients stabilize at sub-maximum producing target effect with acceptable side effects. Going to max just because available is not required.